Xofluza: An effective anti-flu drug

. Roche announced that in the
IIIBLOCKSTONE
study, the risk of influenza was significantly reduced by
86
% compared to placebo, using
Xofluza
for preventive treatment after contact with infected family members.
The results showed that only
1.9
percent of family members treated with
Xofluza
had influenza, compared with
13.6
percent in the placebo treatment group, a benefit that is still statistically significant compared to placebo.
The risk of influenza complications in family contacts was observed to be higher (
2.2
per cent:
15.4
per cent), and children under the age of
12,
were more likely to develop influenza (
4.2
per cent:
15.5
per cent).
The company also announced that the drug is as safe as a placebo, with the overall occurrence of adverse events in
Xofluza
and placebo at
22.2
% and
20.5
%, respectively.
In addition, the study showed that even with lower flu standards, the
risk of influenza among family members was
significantly reduced by
76
percent (
5.3
percent:
22.4
percent) compared to a placebo.
“
Because influenza viruses can quickly infect people around us, limiting the spread of influenza in infected homes has the potential to avoid having a significant impact on the wider community
-
, a key step in the global fight against influenza.
"
Sandra

Horning
, chief medical officer and head of global product development at
Roche, said,
"We are encouraged by Blockstone
's research, which is the first to show that
Xofluza
is an effective preventive treatment after exposure to influenza, and we look forward to sharing this data with health authorities."
”
Xofluza
is the first and only oral drug approved for use in the treatment of influenza in other healthy patients, and the first new influenza drug with a new mechanism of effect approved by the
FDA
in the last
20
years.
（cyy123.com）